亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial

医学 安慰剂 祖细胞 冲程(发动机) 内科学 骨髓 外科 干细胞 病理 遗传学 机械工程 生物 工程类 替代医学
作者
David C. Hess,Lawrence R. Wechsler,Wayne M. Clark,Sean I. Savitz,Gary A. Ford,David Chiu,Dileep R Yavagal,Ken Uchino,David S. Liebeskind,Alexander P. Auchus,Souvik Sen,Cathy Sila,Jeffrey Vest,Robert W. Mays
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:16 (5): 360-368 被引量:360
标识
DOI:10.1016/s1474-4422(17)30046-7
摘要

Background Multipotent adult progenitor cells are a bone marrow-derived, allogeneic, cell therapy product that modulates the immune system, and represents a promising therapy for acute stroke. We aimed to identify the highest, well-tolerated, and safest single dose of multipotent adult progenitor cells, and if they were efficacious as a treatment for stroke recovery. Methods We did a phase 2, randomised, double-blind, placebo-controlled, dose-escalation trial of intravenous multipotent adult progenitor cells in 33 centres in the UK and the USA. We used a computer-generated randomisation sequence and interactive voice and web response system to assign patients aged 18–83 years with moderately severe acute ischaemic stroke and a National Institutes of Health Stroke Scale (NIHSS) score of 8–20 to treatment with intravenous multipotent adult progenitor cells (400 million or 1200 million cells) or placebo between 24 h and 48 h after symptom onset. Patients were ineligible if there was a change in NIHSS of four or more points during at least a 6 h period between screening and randomisation, had brainstem or lacunar infarct, a substantial comorbid disease, an inability to undergo an MRI scan, or had a history of splenectomy. In group 1, patients were enrolled and randomly assigned in a 3:1 ratio to receive 400 million cells or placebo and assessed for safety through 7 days. In group 2, patients were randomly assigned in a 3:1 ratio to receive 1200 million cells or placebo and assessed for safety through the first 7 days. In group 3, patients were enrolled, randomly assigned, and stratified by baseline NIHSS score to receive 1200 million cells or placebo in a 1:1 ratio within 24–48 h. Patients, investigators, and clinicians were masked to treatment assignment. The primary safety outcome was dose-limiting toxicity effects. The primary efficacy endpoint was global stroke recovery, which combines dichotomised results from the modified Rankin scale, change in NIHSS score from baseline, and Barthel index at day 90. Analysis was by intention to treat (ITT) including all patients in groups 2 and 3 who received the investigational agent or placebo. This study is registered with ClinicalTrials.gov, number NCT01436487. Findings The study was done between Oct 24, 2011, and Dec 7, 2015. After safety assessments in eight patients in group 1, 129 patients were randomly assigned (67 to receive multipotent adult progenitor cells and 62 to receive placebo) in groups 2 and 3 (1200 million cells). The ITT populations consisted of 65 patients who received multipotent adult progenitor cells and 61 patients who received placebo. There were no dose-limiting toxicity events in either group. There were no infusional or allergic reactions and no difference in treatment-emergent adverse events between the groups (64 [99%] of 65 patients in the multipotent adult progenitor cell group vs 59 [97%] of 61 in the placebo group). There was no difference between the multipotent adult progenitor cell group and placebo groups in global stroke recovery at day 90 (odds ratio 1·08 [95% CI 0·55–2·09], p=0·83). Interpretation Administration of multipotent adult progenitor cells was safe and well tolerated in patients with acute ischaemic stroke. Although no significant improvement was observed at 90 days in neurological outcomes with multipotent adult progenitor cells treatment, further clinical trials evaluating the efficacy of the intervention in an earlier time window after stroke (<36 h) are planned. Funding Athersys Inc.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
何在完成签到,获得积分10
3秒前
Lucas的应助被DTS采纳,获得10
4秒前
6秒前
Ziezer完成签到,获得积分10
7秒前
初初初啊发布了新的文献求助10
7秒前
生性不爱说话完成签到,获得积分10
9秒前
DTS完成签到,获得积分10
11秒前
可爱多婷婷子完成签到 ,获得积分10
11秒前
单身的曲奇完成签到,获得积分10
12秒前
霸气的远望完成签到 ,获得积分10
15秒前
15秒前
Nole的应助被pursuit采纳,获得30
16秒前
迪恩关注了科研通微信公众号
19秒前
初初初啊发布了新的文献求助10
20秒前
reece完成签到 ,获得积分10
22秒前
葡萄味的果茶完成签到 ,获得积分10
24秒前
LeoYiS214完成签到,获得积分10
25秒前
26秒前
28秒前
梨理完成签到 ,获得积分10
29秒前
秀丽战斗机关注了科研通微信公众号
30秒前
30秒前
Nole的应助被科研通管家采纳,获得10
30秒前
30秒前
Hello的应助被科研通管家采纳,获得10
30秒前
30秒前
田様的应助被科研通管家采纳,获得10
30秒前
SciGPT的应助被科研通管家采纳,获得10
30秒前
30秒前
polymer1Ma发布了新的文献求助10
31秒前
隐形曼青的应助被科研通管家采纳,获得10
31秒前
31秒前
尊敬的芷卉完成签到,获得积分10
31秒前
Jasper的应助被科研通管家采纳,获得10
31秒前
31秒前
小蘑菇的应助被科研通管家采纳,获得10
31秒前
PhysicsXX完成签到,获得积分10
33秒前
34秒前
34秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190060
求助须知:如何正确求助?哪些是违规求助? 9577165
关于积分的说明 21851884
捐赠科研通 7788155
什么是DOI,文献DOI怎么找? 3436233
关于科研通互助平台的介绍 2559935
邀请新用户注册赠送积分活动 2482792